A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Pazopanib (Primary)
- Indications Chondrosarcoma; Soft tissue sarcoma; Solitary-fibrous-tumour
- Focus Therapeutic Use
- 26 Sep 2019 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
- 19 Jul 2019 Results from cohort of patients with advanced extraskeletal myxoid chondrosarcoma (n=26; data cutoff Oct 9, 2018) published in the Lancet Oncology
- 04 Jun 2019 Results (n=34) assessing outcomes of typical solitary fibrous tumors (T-SFT) cohort, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.